Dendreon Data Has Analyzation Problems and 1 Stocks that Has Hit 52-Week Lows

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Dell Inc. (NASDAQ:DELL): Fingerprint-reading software that Apple (NASDAQ:AAPL) gained via its acquisition of Authentec, has some vulnerabilities possibly allowing hackers to access Windows (NASDAQ:MSFT) account passwords, according to Boy Genius Report. The software is already pre-installed on laptops sold by Dell (NASDAQ:DELL), Sony (NYSE:SNE), and others. The shares closed at $9.35, down $0.08 or 0.85% on the day. They have traded in a 52-week range of $9.34 to $18.36.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Dendreon Corp. (NASDAQ:DNDN): Data from clinical trials of Dendreon’s Provenge, used to treat cancer, was analyzed differently by researchers than the company informed the FDA that it would be, according to Reuters. The publication also cites experts in biostatistics and clinical trials who have been stating that the analysis “was a departure from scientific norms.” The shares closed at $4.35, up $0.14 or 3.33% on the day. They have traded in a 52-week range of $4.17 to $17.04.

Don’t Miss: Election 2012: Here’s a Peek at Potential Winning and Losing Stocks.


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business